je.st
news
Tag: results
Range Resources Details 2Q Financial Results
2014-07-29 16:46:00| OGI
There was $766 million in total revenues for the second quarter, the company said.
Tags: results
details
range
resources
International Paper 2Q 2014 results: operating earnings up 42% from year ago to $409 million
2014-07-29 16:14:36| Paper - Topix.net
International Paper today reported second quarter 2014 net earnings attributable to common shareholders totaling $161 million compared with a net loss of $95 million in the first quarter of 2014, which included a pre-tax charge of $495 million associated with the Courtland mill shutdown, and net earnings of $259 million in the second quarter of ... (more)
Tags: to
year
results
international
Antibe Therapeutics Reports Year-End Financial and Operating Results
2014-07-29 14:59:53| Semiconductors - Topix.net
Antibe Therapeutics Inc. filed its financial and operating results today for the fourth quarter and the year ended March 31, 2014.
Tags: results
reports
financial
operating
United Airlines Results Impress Wall Street; Pilots Are Doubtful
2014-07-29 13:02:44| Airlines - Topix.net
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Tags: results
united
street
wall
Merck Announces Second-Quarter 2014 Financial Results
2014-07-29 12:56:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Second-Quarter 2014 Non-GAAP EPS of $0.85, Excluding Certain Items, and GAAP EPS of $0.68 2014 Full-Year Non-GAAP EPS Target of $3.43 to $3.53, Excluding Potential Venezuelan Bolivar Devaluation and Certain Other Items; 2014 Full-Year GAAP EPS Target of $4.44 to $4.77 2014 Full-Year Non-GAAP EPS Target Includes $0.06 to $0.09 Anticipated Dilution From Planned Sale of Merck Consumer Care and Research Collaboration With Bayer, and Planned Acquisition of Idenix Generated Worldwide Sales of $10.9 Billion, a Decrease of 1 Percent, Reflecting Unfavorable Impact of Patent Expiries, Divested Products and Decline in Sales of Hepatitis C Products Grew Top Five Franchises by 6 Percent in Total Pembrolizumab (MK-3475), an Investigational Anti-PD-1 Antibody, Accepted in Second Quarter for Regulatory Review in Both the United States and European Union WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2014. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Lainie Keller, 908-423-4187orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Sites : [730] [731] [732] [733] [734] [735] [736] [737] [738] [739] [740] [741] [742] [743] [744] [745] [746] [747] [748] [749] next »